Literature DB >> 21116174

Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats.

Alessandra Giarola1, Alessia Auber, Cristiano Chiamulera.   

Abstract

Acetylcholinesterase inhibitors (AChE-Is), galantamine, physostigmine and tacrine, enhance central levels of synaptic acetylcholine. Galantamine and physostigmine, but not tacrine, exhibit allosteric potentiation ligand (APL) properties on nicotinic acetylcholine receptors. The purpose of this study was to investigate whether AChE-Is with nicotinic acetylcholine receptor-positive allosteric modulator properties generalize to the discriminative stimulus effect of nicotine in rats. A two-lever operant conditioning paradigm was used in which rats were trained to discriminate nicotine (0.2 mg/kg/ml intraperitoneally) from saline. After training, generalization tests were carried out with galantamine (1, 3 or 5 mg/kg intraperitoneally), physostigmine (0.05, 0.1 or 0.2 mg/kg subcutaneously) or tacrine (0.625, 1.25 or 2.5 mg/kg subcutaneously) given as a single presession administration. Galantamine, physostigmine or tacrine produced a partial generalization of 62.2%, 55.1% or 43.6% , respectively, on the nicotine-appropriate lever compared with 100% partial generalization induced by the nicotine-training dose. High doses of galantamine, physostigmine or tacrine produced small but significant decreases in operant response rate, suggesting a possible underestimation of the degree of generalization. Our study showed that these three AChE-Is partially generalized to the nicotine stimulus without a significant distinction between AChE-Is with or without APL properties. These findings suggest that the APL property is not necessary for inducing nicotine-like effects in vivo in this behavioural paradigm.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21116174     DOI: 10.1097/FBP.0b013e328341e9dd

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  7 in total

1.  Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.

Authors:  Blake A Kimmey; Laura E Rupprecht; Matthew R Hayes; Heath D Schmidt
Journal:  Addict Biol       Date:  2012-12-12       Impact factor: 4.280

2.  Nicotine-like discriminative stimulus effects of acetylcholinesterase inhibitors and a muscarinic receptor agonist in Rhesus monkeys.

Authors:  Megan J Moerke; Lance R McMahon
Journal:  Drug Dev Ind Pharm       Date:  2019-02-22       Impact factor: 3.225

3.  Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.

Authors:  Mehmet Sofuoglu; Aryeh I Herman; Yisheng Li; Andrew J Waters
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

4.  Mucuna pruriens Seed Aqueous Extract Improved Neuroprotective and Acetylcholinesterase Inhibitory Effects Compared with Synthetic L-Dopa.

Authors:  Narisa Kamkaen; Chuda Chittasupho; Suwanna Vorarat; Sarin Tadtong; Watoo Phrompittayarat; Siriporn Okonogi; Pakakrong Kwankhao
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

Review 5.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 6.  Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.

Authors:  Rebecca L Ashare; Heath D Schmidt
Journal:  Expert Opin Drug Discov       Date:  2014-04-07       Impact factor: 6.098

7.  Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers.

Authors:  R L Ashare; B A Kimmey; L E Rupprecht; M E Bowers; M R Hayes; H D Schmidt
Journal:  Transl Psychiatry       Date:  2016-01-19       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.